Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Oh

Showing results (491-500 of 552) with videos related to

Pageof 56
Sort By:
Nature Cancer|December 29, 2022
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progressionTim Kong, Angelo B A Laranjeira, Kangning Yang, et al.
Nature Genetics|January 20, 2009
DNA methylation profiles in monozygotic and dizygotic twinsZachary A Kaminsky, Thomas Tang, Sun-Chong Wang, et al.
Blood Advances|September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trialStephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Cancer Discovery|July 1, 2021
A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative NeoplasmsHamza Celik, Ethan Krug, Christine R Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
The Journal of Clinical Investigation|December 7, 2023
Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasmsFan He, Angelo Ba Laranjeira, Tim Kong, et al.
Hemasphere|November 1, 2023
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 TrialsJean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, et al.
Blood Advances|August 8, 2023
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosisStephen T Oh, Ruben A Mesa, Claire N Harrison, et al.
Clinical Transplantation|October 28, 2023
The utilization of molecular microscope in management of heart transplant recipients in the era of noninvasive monitoringYonatan Mehlman, Andrea Fernendez Valledor, Cathrine Moeller, et al.
Science Translational Medicine|September 23, 2016
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemiaRizwan Romee, Maximillian Rosario, Melissa M Berrien-Elliott, et al.
Pageof 56

Showing results (491-500 of 552) with videos related to

Sort By:
Pageof 56
Nature Cancer|December 29, 2022
DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progressionTim Kong, Angelo B A Laranjeira, Kangning Yang, et al.
Nature Genetics|January 20, 2009
DNA methylation profiles in monozygotic and dizygotic twinsZachary A Kaminsky, Thomas Tang, Sun-Chong Wang, et al.
Blood Advances|September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trialStephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Cancer Discovery|July 1, 2021
A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative NeoplasmsHamza Celik, Ethan Krug, Christine R Zhang, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
The Journal of Clinical Investigation|December 7, 2023
Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasmsFan He, Angelo Ba Laranjeira, Tim Kong, et al.
Hemasphere|November 1, 2023
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 TrialsJean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, et al.
Blood Advances|August 8, 2023
Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosisStephen T Oh, Ruben A Mesa, Claire N Harrison, et al.
Clinical Transplantation|October 28, 2023
The utilization of molecular microscope in management of heart transplant recipients in the era of noninvasive monitoringYonatan Mehlman, Andrea Fernendez Valledor, Cathrine Moeller, et al.
Science Translational Medicine|September 23, 2016
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemiaRizwan Romee, Maximillian Rosario, Melissa M Berrien-Elliott, et al.
Pageof 56